EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy

Christian Immanuel, Thomas Büttner, Alois M Sprinkart, Sebastian Nowak, Maike Theis, Jim Küppers, Sibgol Fazeli, Leander Fritzsche, Aland Amin, Dilan Salih, Hojjat Ahmadzadehfar, Florian C Gärtner und 6 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08068-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Christian Immanuel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Muscle, Skeletal, Dipeptides. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Skeletal muscle radiodensity (SMD) is an emerging imaging-derived marker of muscle quality. Its prognostic relevance in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy has not yet been systematically evaluated. This study aims to investigate the prognostic value of SMD derived from routine pretherapeutic PET/CT imaging in a large real-world mCRPC cohort treated with [¹⁷⁷Lu]Lu-PSMA-617.

Methods

In this single-center study, the largest to date cohort comprising 410 mCRPC patients was analyzed. SMD was quantified automatically from the L3-level CT component of pretherapeutic [⁶⁸Ga]Ga-PSMA-PET/CT using an AI-based segmentation tool. An optimal SMD cut-off (19.26 HU) was determined for survival stratification. Associations with overall survival (OS) were assessed using multivariable Cox regression (univariable and multivariable, adjusted for baseline PSA) and Kaplan-Meier analysis.

Results

Lower SMD was associated with reduced OS (HR 1.87, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyMuscle, SkeletalDipeptidesHeterocyclic Compounds, 1-RingGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedAutomationPrognosisNeoplasm MetastasisMiddle AgedSurvival AnalysisLigandsRadiopharmaceuticalsAged, 80 and over

Stichwörter der Autor:innen

Castration-Resistant Prostate CancerLutetium-177PSMASkeletal muscle radiodensitySurvival predictor

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLigandsGlutamate Carboxypeptidase IIRadiopharmaceuticalsAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
  • Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany.
  • Department of Nuclear Medicine, Institute of Radiology, Neuroradiology and Nuclear Medicine, Knappschaft Kliniken, University Hospital Bochum, Bochum, Germany.
  • Department of Nuclear Medicine, Knappschaft Kliniken Westfalen Dortmund, Dortmund, Germany.
  • Department of Psychosomatic Medicine and Psychotherapy, University Hospital Muenster, Muenster, Germany.

Förderung

  • Universitätsklinikum Bonn

Zitieren

APA

Immanuel, C., Büttner, T., Sprinkart, A. M., Nowak, S., Theis, M., Küppers, J., Fazeli, S., Fritzsche, L., Amin, A., Salih, D., Ahmadzadehfar, H., Gärtner, F. C., Kreppel, B., Conrad, R., Ritter, M., Essler, M., Krausewitz, P., & Marinova, M. (2026). Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08068-x

Vancouver

Immanuel C, Büttner T, Sprinkart AM, Nowak S, Theis M, Küppers J, et al. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08068-x

BibTeX
@article{Immanuel2026,
  author = {Immanuel, Christian and Büttner, Thomas and Sprinkart, Alois M and Nowak, Sebastian and Theis, Maike and Küppers, Jim and Fazeli, Sibgol and Fritzsche, Leander and Amin, Aland and Salih, Dilan and Ahmadzadehfar, Hojjat and Gärtner, Florian C and Kreppel, Barbara and Conrad, Rupert and Ritter, Manuel and Essler, Markus and Krausewitz, Philipp and Marinova, Milka},
  title = {Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08068-x}
}
Kostenlos starten →